세계 골수 이식 시장 : 이식 유형별, 적응 질환별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Bone Marrow Transplant Market is accounted for $10.65 billion in 2023 and is expected to reach $15.39 billion by 2030 growing at a CAGR of 5.4% during the forecast period. In the interior of long bones, there is a soft vascular tissue called bone marrow. Hematopoietic and mesenchymal stem cells make up both types of stem cells. The main functions of bone marrow are hematopoiesis, lymphocyte production, and fat storage. Additionally, a unique form of treatment for people with certain cancers, such as leukemia, lymphoma, or other conditions, is bone marrow transplantation (BMT). Stem cells that are typically found in the bone marrow are removed during a bone marrow transplant, filtered, and then returned to the donor (patient) or to another individual.

According to data provided by the American Cancer Society, Inc., a voluntary health organization dedicated to eliminating cancer, in January 2022, Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the U.S., accounting for about 4% of all cancers.

Market Dynamics:

Driver:

Increasing incidence of haematological disorders

Hematological disorders like leukemia, lymphoma, and multiple myeloma are becoming more commonplace in the world. Environmental exposures, alterations in lifestyle, and an aging population all play a role. Furthermore, as a result of improvements in diagnostics and early detection techniques, more cases are now being discovered at an earlier stage, which has raised interest in bone marrow transplantation as a potential treatment or cure. The number of patients who can benefit from transplantation has also increased as a result of the development of targeted therapies and precision medicine techniques, which can be combined with transplants to improve outcomes.

Restraint:

High transplantation costs

The high price of the procedure is one of the main barriers to the market for bone marrow transplants. The evaluation prior to the transplant, the conditioning regimens, the actual transplant, the post-transplant care, and long-term follow-up are all expensive procedures. Many patients may find these costs to be a barrier to care, even in areas with highly developed healthcare systems. Additionally, insurance might not always pay the full cost, leaving patients with sizable financial burdens.

Opportunity:

Modernization of personalized medicine

The field of bone marrow transplantation is greatly impacted by personalized medicine, which is driven by genomic and molecular profiling. Based on a person's genetic and molecular profile, it is possible to improve transplant outcomes and lower complications by customizing transplant strategies and post-transplant therapies. Moreover, this strategy reduces negative effects while improving the general efficacy of transplantation.

Threat:

Healthcare costs and economic constraints

The significant financial burden it places on patients and healthcare systems is one of the main threats to the bone marrow transplant market. Many patients may choose not to undergo transplantation due to the high costs involved, including those of pre-transplant evaluation, conditioning regimens, the actual transplantation, post-transplant care, and long-term follow-up. Additionally, high medical expenses can also put a strain on insurance plans and prevent underserved populations from receiving transplants.

COVID-19 Impact:

On the market for bone marrow transplants, the COVID-19 pandemic had a sizable effect. Worldwide healthcare systems were affected by the pandemic, which included the postponement or cancellation of non-urgent transplant procedures in order to conserve healthcare resources and reduce infection risks for susceptible patients. However, as concerns about transplant recipients Immuno-compromised states increased, strict infection control measures and modifications to transplant protocols became necessary.

The Leukemia segment is expected to be the largest during the forecast period

In the bone marrow transplant market, leukemia holds the largest market share. One of the most common and well-known causes of bone marrow transplantation is leukemia, which is characterized by the abnormal proliferation of white blood cells. The high prevalence of different leukemia types, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), significantly increases the demand for transplantation services. Moreover, the success rates for leukemia patients have also improved thanks to improvements in transplant methods, supportive care, and targeted therapies, which have further fueled this market's expansion.

The Ambulatory Surgical Centers segment is expected to have the highest CAGR during the forecast period

The bone marrow transplant market's, Ambulatory Surgical Centers (ASCs) segment holds the highest CAGR. ASCs provide a variety of outpatient surgical procedures, including some medical treatments and minimally invasive surgeries. Their growing popularity is a result of their capacity to offer affordable and practical healthcare, shorter hospital stays, and lower infection risks. Additionally, ASCs have diversified their offerings in recent years to include a number of specialties, such as orthopedics, ophthalmology, gastroenterology, and pain management.

Region with largest share:

The North American region holds the largest market share for bone marrow transplants. This dominance can be attributed to a number of things, including a strong regulatory environment, an established healthcare infrastructure, a high prevalence of haematological disorders requiring bone marrow transplants, and cutting-edge medical technologies. Additionally, North America benefits from extensive research and development efforts, significant healthcare expenditures, and a sizable donor pool. The region's market leadership has also been aided by growing patient and healthcare provider awareness of the advantages of bone marrow transplantation.

Region with highest CAGR:

The market for bone marrow transplants has seen the highest CAGR in the Middle East and North Africa (MENA) region. Increased healthcare investments, a growing healthcare infrastructure, and rising public awareness of cutting-edge treatments like bone marrow transplants are a few of the factors driving this growth. Moreover, the United Arab Emirates, Saudi Arabia, and Qatar are among the MENA nations that have made significant improvements to their healthcare infrastructure, enabling their populations to access bone marrow transplantation more easily. The rising demand for transplantation services is also a result of the region's increasing prevalence of haematological disorders, which is fueling the market's expansion.

Key players in the market:

Some of the key players in Bone Marrow Transplant market include: Gamida Cell Ltd., Mesoblast Ltd., American Type Culture Collection (ATCC) Inc, Lonza Group Ltd., FUJIFILM Cellular Dynamics, Inc., ReachBio LLC., Sanofi-Aventis LLC., PromoCell GmbH, Abbott Laboratories Inc, The Emmes Company LLC, CORESTEM, Inc., StemCell Technologies., Hemacare Corporation, AllCells LLC., Lifeline Cell Technology LLC, ReeLabs Pvt. Ltd., Charles River Laboratories and Merck Millipore Corporation .

Key Developments:

In June 2023, Lonza, a trusted partner of the pharmaceutical, biotech, and nutrition industries, has entered into a ten-year Virtual Power Purchase Agreement with IGNIS. A VPPA represents a tailored and adaptable solution that caters to the needs of companies like Lonza, which operates in multiple sites. Unlike traditional power purchase agreements, VPPAs offer more flexibility and attract investments in the solar electricity production facilities as they are not linked to photovoltaic production facilities through physical grids.

In January 2023, FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics' iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.

In October 2020, Gamida Cell Ltd., a leading cellular and immune therapeutics company, and Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their existing strategic collaboration for omidubicel, Gamida Cell's advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of an allogeneic hematopoietic stem cell transplant.

Transplant Types Covered:

• Autologous Bone Marrow Transplant
• Allogeneic Bone marrow Transplant
• Other Transplant Types

Disease Indications Covered:

• Leukemia
• Lymphoma
• Myeloma
• Thalassemia
• Myelodysplastic Syndrome
• Myeloproliferative Disorders
• Aplastic Anemia
• Solid Tumors
• Sickle cell Anemia
• Other Disease Indications

End Users Covered:

• Hospitals
• Multispecialty Clinics
• Ambulatory Surgical Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Bone Marrow Transplant Market, By Transplant Type

• 5.1 Introduction
• 5.2 Autologous Bone Marrow Transplant
• 5.3 Allogeneic Bone marrow Transplant
• 5.4 Other Transplant Types

6 Global Bone Marrow Transplant Market, By Disease Indication

• 6.1 Introduction
• 6.2 Leukemia
• 6.3 Lymphoma
• 6.4 Myeloma
• 6.5 Thalassemia
• 6.6 Myelodysplastic Syndrome
• 6.7 Myeloproliferative Disorders
• 6.8 Aplastic Anemia
• 6.9 Solid Tumors
• 6.10 Sickle cell Anemia
• 6.11 Other Disease Indications

7 Global Bone Marrow Transplant Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Multispecialty Clinics
• 7.4 Ambulatory Surgical Centers
• 7.5 Other End Users

8 Global Bone Marrow Transplant Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Gamida Cell Ltd.
• 10.2 Mesoblast Ltd.
• 10.3 American Type Culture Collection (ATCC) Inc
• 10.4 Lonza Group Ltd.
• 10.5 FUJIFILM Cellular Dynamics, Inc.
• 10.6 ReachBio LLC.
• 10.7 Sanofi-Aventis LLC.
• 10.8 PromoCell GmbH
• 10.9 Abbott Laboratories Inc
• 10.10 The Emmes Company LLC
• 10.11 CORESTEM, Inc.
• 10.12 StemCell Technologies.
• 10.13 Hemacare Corporation
• 10.14 AllCells LLC.
• 10.15 Lifeline Cell Technology LLC
• 10.16 ReeLabs Pvt. Ltd.
• 10.17 Charles River Laboratories
• 10.18 Merck Millipore Corporation